Home/Filings/4/0001209191-14-014153
4//SEC Filing

Conatus Pharmaceuticals Inc 4

Accession 0001209191-14-014153

CIK 0001383701operating

Filed

Feb 24, 7:00 PM ET

Accepted

Feb 25, 5:37 PM ET

Size

15.8 KB

Accession

0001209191-14-014153

Insider Transaction Report

Form 4
Period: 2014-02-19
KLINGENSTEIN PAUL H
Director10% Owner
Transactions
  • Other

    Common Stock

    2014-02-1930,21622,203 total(indirect: By Aberdare Partners III, L.P.)
  • Other

    Common Stock

    2014-02-19+36,63436,634 total(indirect: By Aberdare GP III, L.L.C.)
  • Other

    Common Stock

    2014-02-1936,6340 total(indirect: By Aberdare GP III, L.L.C.)
  • Other

    Common Stock

    2014-02-19+8,7318,731 total(indirect: By Trust)
  • Other

    Common Stock

    2014-02-191,283,589943,355 total(indirect: By Aberdare Ventures III, L.P.)
  • Other

    Common Stock

    2014-02-19+20,32220,322 total
Footnotes (7)
  • [F1]Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Aberdare Ventures III, L.P. ("Aberdare Ventures III") without consideration to its limited partners and its general partner, Aberdare GP III, L.L.C. ("Aberdare GP III").
  • [F2]Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Aberdare Partners III, L.P. ("Aberdare Partners III") without consideration to its limited partners and its general partner, Aberdare GP III.
  • [F3]The Reporting Person is a Managing Director of Aberdare GP III, L.L.C. ("Aberdare GP III") which serves as the sole General Partner of Aberdare Ventures III and Aberdare Partners III. As such, the Reporting Person shares voting and investment control over the securities owned by Aberdare Ventures III and Aberdare Partners III, and may be deemed to own beneficially the securities held by Aberdare Ventures III and Aberdare Partners III. The Reporting Person disclaims beneficial ownership of the shares held by Aberdare Ventures III and Aberdare Partners III except to the extent of his proportionate pecuniary interest therein.
  • [F4]Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer by Aberdare Ventures III and Aberdare Partners III described in footnotes 1 and 2.
  • [F5]Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Aberdare GP III without consideration to its members.
  • [F6]Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer by Aberdare GP III described in footnote 5.
  • [F7]Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer by Aberdare GP III described in footnote 5. The shares are held by the Klingenstein-Bole 2003 Irrevocable Children's Trust (the "Trust"). The Reporting Person is a trustee of the Trust. The Reporting Person disclaims beneficial ownership of the shares held by the Trust except to the extent of his proportionate pecuniary interest therein.

Issuer

Conatus Pharmaceuticals Inc

CIK 0001383701

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001383701

Filing Metadata

Form type
4
Filed
Feb 24, 7:00 PM ET
Accepted
Feb 25, 5:37 PM ET
Size
15.8 KB